LY294002 是一种广谱 PI3K 抑制剂,抑制 PI3Kα, PI3Kδ 和 PI3Kβ的 IC50 分别为 0.5, 0.57, 0.97 μM。 它也可抑制 CK2的活性,IC50 为 98 nM。
Description |
LY294002 is a broad-spectrum inhibitor of PI3K with IC50s of 0.5, 0.57, 0.97 μM for PI3Kα, PI3Kδ PI3Kβ, respectively. It also inhibits CK2 with an IC50 of 98 nM. |
||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
IC50 & Target[1] |
|
||||||||||||||||
In Vitro |
LY294002 (5 μM) completely inhibits the phosphorylation of PKB In HepG2 cells. LY294002 (5 μM) is also shown to block insulin-induced phosphorylation of PKB Ser473 in CHO-IR cells[1]. LY294002 is also a potent inhibitor of CK2 (casein kinase 2) with IC50 of 98 nM. LY294002 is also able to reduce the kinase activity of both isoforms of the serine/threonine kinases GSK3α β[2]. When the CNE-2Z cell line is cultured in medium containing LY294002(0 μM, 10 μM, 25 μM, 50 μM, 75 μM) for 24 h 48 h, cell proliferation is remarkably decreased in a dose-dependent fashion[3]. |
||||||||||||||||
In Vivo |
Treatment with LY294002 (i.p.,50 mg/kg, 75 mg/kg) significantly reduces mean NPC tumor burden as compared with the control group. Treatment with 10 mg/kg 25 mg/kg LY294002 is less effective in decreasing tumor burden. Mean NPC tumor burden treated with LY294002 is remarkably decreased in a dose-dependent manner, whereas mean body weight is no obvious difference between control treated groups (LY294002, 10 mg/kg, 25 mg/kg, 50 mg/kg, 75 mg/kg)[3]. |
||||||||||||||||
Solvent & Solubility |
In Vitro:
DMSO : 14.9 mg/mL (48.48 mM; Need ultrasonic warming)
Preparing
Stock Solutions
* Please refer to the solubility information to the appropriate solvent.
In Vivo:
|
||||||||||||||||
References |
|
温馨提示:因厂家更改产品包装、产地或者更换随机附件等没有任何提前通知,且每位咨询者购买情况、提问时间等不同,为此以下回复仅对提问者3天内有效,其他网友仅供参考!若由此给您带来不便请多多谅解,谢谢!
服务热线
0771-3293894